Status:
COMPLETED
Methylphenidate and Response to Alcohol Cues
Lead Sponsor:
University of Florida
Conditions:
Alcohol Use Disorder
Attention Deficit Hyperactivity Disorder
Eligibility:
All Genders
18-25 years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this study is to determine whether changes in attention levels related to taking a single dose of a medication called methylphenidate, also known as Ritalin, affects responses to alcoho...
Detailed Description
Recent studies have revealed a robust link between attentional ability and resilience against stress-related psychopathology, in general, and against alcohol use disorder (AUD) specifically. For examp...
Eligibility Criteria
Inclusion
- Adults ages 18-25 years
- Meets DSM-5 criteria for AUD
- Meets DSM-5 criteria for ADHD
- Fluent in English
- Normal or corrected to normal vision
Exclusion
- Meets DSM-5 criteria for bipolar disorder, psychotic disorders, neurological disorders, or substance use disorders other than AUD.
- Participant routinely uses psychoactive drugs or medications except for non-dependent marijuana or nicotine use (due to common use of these substances in individuals with AUD).
- Participant has contraindications for taking methylphenidate.
- Participant has contraindications for being in an MRI machine
- Self-reported history of high blood pressure over 140/90 or consistent readings of 140/90 or above upon arrival for a session.
- History of seizure disorder
- Liver disease
- Participant is currently pregnant or trying to become pregnant
Key Trial Info
Start Date :
March 20 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2025
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT06063200
Start Date
March 20 2024
End Date
July 1 2025
Last Update
July 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Gainesville, Florida, United States, 32610